Atossa Therapeutics, Inc. (ATOS) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females.
McCune-Albright Syndrome is a rare genetic disorder caused by mutations in the GNAS gene, leading to endocrine abnormalities.
The Rare Pediatric Disease designation is given to drug candidates targeting serious or life-threatening conditions that primarily affect individuals from birth to 18 years of age. If approved, the drug may qualify for a Priority Review Voucher, which can be used to obtain priority review for a future application or sold to another company.
Recent Priority Review Voucher sales have ranged from about $100 million to $205 million.
Atossa shares were up more than 1% in pre-market trading after closing at $5.33 on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.